ReviewPharmacology, biochemistry, and behavior2012
Novel glutamatergic agents for major depressive disorder and bipolar disorder.
Review in Pharmacology, biochemistry, and behavior, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Epigenetics of bipolar disorder: a bibliometric landscape and visualization analysis.Frontiers in psychiatry · 2026Pooled it
- A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression.Journal of clinical psychopharmacology · 2017Trial
- Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.The Journal of clinical psychiatry · 2013Trial
- Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Neurotoxicity-Based Toxicometabolomics ofACS omega · 2025Article
- The Association Among Bipolar Disorder, Mitochondrial Dysfunction, and Reactive Oxygen Species.Biomolecules · 2025Review
- From trauma to depression: structural, synaptic, epigenetic, and molecular pathways linking early stress to lifelong vulnerability.Frontiers in psychiatry · 2025Review
- Danggui Buxue Decoction Alleviates Acute Hypoxia-Induced Sleep Disorders: Insights from in vivo and in silico Analyses.Drug design, development and therapy · 2025Article
- Review
- Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Variation along P2RX7 interacts with early traumas on severity of anxiety suggesting a role for neuroinflammation.Scientific reports · 2023Article
- Blood Glutamate Scavenging With Pyruvate as a Novel Preventative and Therapeutic Approach for Depressive-Like Behavior Following Traumatic Brain Injury in a Rat Model.Frontiers in neuroscience · 2022Article
- Effects of the Radix Ginseng and Semen Ziziphi Spinosae drug pair on the GLU/GABA-GLN metabolic cycle and the intestinal microflora of insomniac rats based on the brain-gut axis.Frontiers in pharmacology · 2022Article
- Genetic variants in the bipolar disorder risk locus SYNE1 that affect CPG2 expression and protein function.Molecular psychiatry · 2021Article
- New Pharmacological Interventions in Bipolar Disorder.Current topics in behavioral neurosciences · 2021Review
- Intracellular Signaling Cascades in Bipolar Disorder.Current topics in behavioral neurosciences · 2021Review
- Cerebrospinal fluid glutamate changes in functional movement disorders.NPJ Parkinson's disease · 2020Article
- Targeting the Neuronal Activity of Prefrontal Cortex: New Directions for the Therapy of Depression.Current neuropharmacology · 2020Article
- Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression.Therapeutic advances in psychopharmacology · 2020Review
- Are 24-hour motor activity patterns associated with continued rapid response to ketamine?Neuropsychiatric disease and treatment · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Mood disorders such as major depressive disorder (MDD) and bipolar disorder (BPD) are common, chronic, recurrent mental illnesses that affect the lives and functioning of millions of individuals worldwide. Growing evidence suggests that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in the pathophysiology of mood disorders as well as the efficacy of glutamatergic agents as novel therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.